Detalhe da pesquisa
1.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 381(21): 2020-2031, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562796
2.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
N Engl J Med
; 378(22): 2093-2104, 2018 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658845
3.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
N Engl J Med
; 376(25): 2415-2426, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28636851
4.
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
J Immunother Cancer
; 10(11)2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36328377
5.
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
J Immunother Cancer
; 10(8)2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35977756
6.
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Eur J Cancer
; 116: 137-147, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31195357
7.
A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions.
Cancer Med
; 4(1): 36-42, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25296628